Drug updated on 10/23/2023

Dosage FormInjection (intravenous: 100mg/5mL, 400mg/20mL (20mg/mL))
Drug ClassEpidermal growth factor receptor (EGFR) antagonist
Ongoing and
Completed Studies


  • Indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): in combination with FOLFOX for first-line treatment.
  • Indicated as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.